Cargando…
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529966/ https://www.ncbi.nlm.nih.gov/pubmed/34691071 http://dx.doi.org/10.3389/fimmu.2021.753319 |
| _version_ | 1784586574865891328 |
|---|---|
| author | Sablerolles, Roos S. G. Goorhuis, Abraham GeurtsvanKessel, Corine H. de Vries, Rory D. Huckriede, Anke L. W. Koopmans, Marion P. G. Lafeber, Melvin Postma, Douwe F. van Baarle, Debbie Visser, Leo G. Dalm, Virgil A. S. H. Kootstra, Neeltje A. Rietdijk, Wim J. R. van der Kuy, P. Hugo M. |
| author_facet | Sablerolles, Roos S. G. Goorhuis, Abraham GeurtsvanKessel, Corine H. de Vries, Rory D. Huckriede, Anke L. W. Koopmans, Marion P. G. Lafeber, Melvin Postma, Douwe F. van Baarle, Debbie Visser, Leo G. Dalm, Virgil A. S. H. Kootstra, Neeltje A. Rietdijk, Wim J. R. van der Kuy, P. Hugo M. |
| author_sort | Sablerolles, Roos S. G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8529966 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85299662021-10-22 Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol Sablerolles, Roos S. G. Goorhuis, Abraham GeurtsvanKessel, Corine H. de Vries, Rory D. Huckriede, Anke L. W. Koopmans, Marion P. G. Lafeber, Melvin Postma, Douwe F. van Baarle, Debbie Visser, Leo G. Dalm, Virgil A. S. H. Kootstra, Neeltje A. Rietdijk, Wim J. R. van der Kuy, P. Hugo M. Front Immunol Immunology Frontiers Media S.A. 2021-09-24 /pmc/articles/PMC8529966/ /pubmed/34691071 http://dx.doi.org/10.3389/fimmu.2021.753319 Text en Copyright © 2021 Sablerolles, Goorhuis, GeurtsvanKessel, de Vries, Huckriede, Koopmans, Lafeber, Postma, van Baarle, Visser, Dalm, Kootstra, Rietdijk and van der Kuy https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Sablerolles, Roos S. G. Goorhuis, Abraham GeurtsvanKessel, Corine H. de Vries, Rory D. Huckriede, Anke L. W. Koopmans, Marion P. G. Lafeber, Melvin Postma, Douwe F. van Baarle, Debbie Visser, Leo G. Dalm, Virgil A. S. H. Kootstra, Neeltje A. Rietdijk, Wim J. R. van der Kuy, P. Hugo M. Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol |
| title | Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol |
| title_full | Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol |
| title_fullStr | Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol |
| title_full_unstemmed | Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol |
| title_short | Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol |
| title_sort | heterologous ad26.cov2.s prime and mrna-based boost covid-19 vaccination regimens: the switch trial protocol |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529966/ https://www.ncbi.nlm.nih.gov/pubmed/34691071 http://dx.doi.org/10.3389/fimmu.2021.753319 |
| work_keys_str_mv | AT sablerollesroossg heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT goorhuisabraham heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT geurtsvankesselcorineh heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT devriesroryd heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT huckriedeankelw heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT koopmansmarionpg heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT lafebermelvin heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT postmadouwef heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT vanbaarledebbie heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT visserleog heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT dalmvirgilash heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT kootstraneeltjea heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT rietdijkwimjr heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol AT vanderkuyphugom heterologousad26cov2sprimeandmrnabasedboostcovid19vaccinationregimenstheswitchtrialprotocol |